CAS: 7623-09-8; 2-Chloropropionyl Chloride

上下游产品

CAS号598-78-7 2-氯丙酸 | CAS号123-38-6 丙醛 | CAS号79-03-8 丙酰氯 | CAS号849585-22-4 2-羟基丙酸 | CAS号7791-25-5 磺酰氯 | CAS号7553-56-2 碘 | CAS号94-36-0 过氧化苯甲酰 | CAS号76-00-6 1,1,1-三氯-2-丙醇 | CAS号7782-50-5 氯气 | CAS号106593-37-7 n-allyl-2-chlor... | CAS号107236-27-1 (9ci)-1-(2-氯-1-... | CAS号54333-75-4 N,N-二乙基-2-氯丙酰胺 | CAS号42275-47-8 2-氯-N-甲基丙酰胺 | CAS号141479-87-0 (4-nitrophenyl)... | CAS号94318-71-5 2-氯-N-丙基丙酰胺 | CAS号38076-63-0 2-氯-1-酚噻嗪-10-丙酮 | CAS号4593-38-8 5-甲基-1-茚酮 | CAS号17639-93-9 2-氯丙酸甲酯 | CAS号19281-31-3 2-氯-N-(邻甲苯基)丙酰胺

丙酰氯置于磺酰氯,碘体系中,化学反应生成 2-氯丙酰氯
参考文献:Kharasch; Brown,Journal Of The American Chemical Society,1940,Vol. 62,P. 928
标题:Kharasch; Brown,Journal Of The American Chemical Society,1940,Vol. 62,P. 928

专利信息

专利号:WO-2020246902-A1
优先权日:2019-06-07
标 题 :An initiator of atrp radical polymerisation, a method of its synthesis, and a method of synthesis of low-dispersion polymer and copolymer using this initiator
发明人：MEGIEL ELÅ»BIETA; ROMAŃSKI JAN; FEDORCZUK MAGDALENA
权利人:UNIV WARSZAWSKI
摘要:An initiator of ATRP radical polymerisation having a functional group with a substituent active in polymerisation process, is characterised in that it is a bifunctional initiator containing at least two functional groups separated by a hydrocarbon moiety Y, where the first functional group has an active substituent X and the second functional group has a protecting group Z, which can be chemically modified with the same or a different substituent than the active substituent X present in the first functional group. A method of synthesis of 2-chloro-N-(2-hydroxyethyl)propionamide initiator, NCPAE, is characterised in that ethanolamine is subjected to an acylation reaction with 2-chloropropionyl chloride in presence of triethylamine (TEA), wherein the reaction is carried out under inert atmosphere at room temperature.

专利号:EP-4423083-A2
优先权日:2021-11-29
标 题:Synthesis of pyrazolone derivative compounds and their effects on cox enzymes
发明人：ÖNAY UÇAR EVREN; DEM RAYAK EREF; BERK BARKIN; YURTTA LEYLA; B LTEK N KALEL SEVDE NUR; AH N ZAFER
权利人:UNIV ISTANBUL MEDIPOL; ISTANBUL UNIV REKTORLUGU; ANADOLU UNIV
摘要:The invention is related to the synthesis of 8 pyrazolone derivative compounds and their activities on COX enzymes.

专利号:WO-9946267-A1
优先权日:1998-03-12
标题 :Modulators of protein tyrosine phosphatases (ptpases)
发明人：MOELLER NIELS PETER HUNDAHL; ANDERSEN HENRIK SUNE; IVERSEN LARS FOGH; OLSEN OLE HVILSTED; BRANNER SVEN; HOLSWORTH DANIEL DALE; BAKIR FARID; JUDGE LUKE MILBURN; AXE FRANK URBAN; JONES TODD KEVIN; RIPKA WILIAM CHARLES; GE YU; UYEDA ROY TERUYUKI
权利人:NOVO NORDISK AS; ONTOGEN CORP
摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:US-6951878-B2
优先权日:1998-03-12
标 题:Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)
发明人：MOELLER NIELS PETER HUNDAHL; ANDERSEN HENRIK SUNE; IVERSEN LARS FOGH; OLSEN OLE HVILSTED; BRANNER SVEN; HOLSWORTH DANIEL DALE; BAKIR FARID; JUDGE LUKE MILBURN; AXE FRANK URBAN; JONES TODD KEVIN; RIPKA WILLIAM CHARLES; GE YU; UYEDA ROY TERUYUKI
权利人:NOVO NORDISK AS
摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. n The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:WO-2014202765-A1
优先权日:2013-06-21
标题 :Preparation of chiral 1-methyl-2,3,4,5-1h-benzodiazepines via asymmetric reduction of alpha-substituted styrenes
发明人：STAVBER GAJ; GAZIC SMILOVIC IVANA; CLUZEAU JEROME; RICHTER FRANK
权利人:LEK PHARMACEUTICALS
摘要:The present invention provides an asymmetric and economic synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine via novel intermediates applying an asymmetric enzymatic, biomimetic or catalytic reduction. The present invention also provides a novel green asymmetric catalytic reduction adapted for an aqueous medium to be applied in the synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine or novel intermediates.

专利号:US-11512097-B2
优先权日:2019-11-25
标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
发明人：ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO
权利人:AMGEN INC
摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5Dâ€?). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.